Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.9K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.9K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

605
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
605
Angina IV: Management01:26

Angina IV: Management

452
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
452
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

435
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
435
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

2.0K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
2.0K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

879
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
879

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A case of presumed homozygous familial hypercholesterolemia.

Journal of clinical lipidology·2026
Same author

Reducing the burden of ischemic stroke with lipid expertise.

Progress in cardiovascular diseases·2025
Same author

Digital Biometrics in Predicting Risk for Obstructive Sleep Apnea and Hypertension: Decentralized, Prospective Cohort Study.

Journal of medical Internet research·2025
Same author

Multimodal AI correlates of glucose spikes in people with normal glucose regulation, pre-diabetes and type 2 diabetes.

Nature medicine·2025
Same author

Cumulative exposure to atherogenic lipoprotein particles in young adults and subsequent incident atherosclerotic cardiovascular disease.

European heart journal·2025
Same author

Epicardial connections across the cavotricuspid isthmus.

HeartRhythm case reports·2025

Related Experiment Video

Updated: Apr 15, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Statins and Nonadherence: Should We RELATE Better?

Alexander Turin1, Jay Pandit2, Neil J Stone2

  • 1Department of Internal Medicine, Loyola University Medical Center, Maywood, IL, USA alexander.turin@lumc.edu.

Journal of Cardiovascular Pharmacology and Therapeutics
|April 2, 2015
PubMed
Summary

Statin nonadherence limits cholesterol-lowering benefits and cardiovascular event reduction. Improving adherence requires a clinician-patient partnership to optimize statin therapy and minimize side effects.

Keywords:
ASCVDnonadherencestatin

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.3K
Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

5.4K

Related Experiment Videos

Last Updated: Apr 15, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.3K
Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

5.4K

Area of Science:

  • Cardiology
  • Pharmacology
  • Health Services Research

Background:

  • Statin nonadherence is a significant barrier to achieving optimal cardiovascular risk reduction.
  • Guidelines recommend statins for high-risk groups, yet nonadherence negates expected benefits and increases healthcare costs.

Purpose of the Study:

  • To explore the challenges and solutions for improving statin adherence.
  • To emphasize the importance of a clinician-patient partnership in optimizing statin therapy.

Main Methods:

  • Review of studies on statin nonadherence and its impact on cardiovascular outcomes.
  • Application of the transtheoretical model of behavior change to address adherence barriers.
  • Development of a structured, patient-centered approach for statin therapy discussions.

Main Results:

  • Nonadherence to statin therapy significantly diminishes or eliminates the cardiovascular benefits compared to placebo.
  • Causes of nonadherence are multifactorial, involving patient, clinician, and health system factors.
  • A clinician-patient partnership focused on understanding benefits and side effects is crucial for improving adherence.

Conclusions:

  • Improving statin adherence is essential for realizing the full benefits of lipid-lowering therapy.
  • A structured, patient-centered approach, potentially guided by behavior change models, can enhance statin adherence.
  • Effective communication and shared decision-making are key to optimizing statin therapy outcomes.